logo
  

NRx Pharma Says Class Action Suit Against Company Dismissed

NRx Pharmaceuticals Inc. (NRXP) said Wednesday that on June 13, 2022, the plaintiffs in the securities class action lawsuit captioned "Dal Bosco v. NRx Pharmaceuticals, Inc. et al." filed a notice in the U.S. District Court for the District of Delaware voluntarily dismissing the action against NRx Pharma and its former officers. The dismissal was made without prejudice.

The company said it continues to focus on the development of NRX-101. It will further evaluate the opportunities for ZYESAMI once it receives the full data from the ACTIV-3b / TESICO NIH Study.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
Activity in the U.S. manufacturing sector slowed by more than expected in the month of September but still saw continued growth, according to a report released by the Institute for Supply Management on Monday. Stocks have moved sharply higher in morning trading on Monday, regaining ground following a dismal September. The major averages have all shown substantial moves to the upside. Swedish geneticist Svante Paabo has won this year's Nobel Prize in Physiology/Medicine for his discoveries concerning the genomes of extinct hominins and human evolution. Through his pioneering research, Svante Pääbo accomplished something seemingly impossible: sequencing the genome of the Neanderthal, an extinct relative of present-day humans. He also made the sensational discovery of a previous
RELATED NEWS
Follow RTT